<DOC>
	<DOC>NCT01073384</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and preliminary efficacy of four doses of SGX201 in subjects with rectal cancer treated with concurrent radiation and chemotherapy.</brief_summary>
	<brief_title>A Dose Ranging Study of Delayed Release Beclomethasone for Prevention of Acute Enteritis in Patients With Rectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Enteritis</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<criteria>Primary rectal cancer Planned course of conventional neoadjuvant radiation therapy before surgery Scheduled to receive chemotherapy &gt;/= 18 years of age Negative pregnancy test History of acute or chronic regional enteritis or inflammatory bowel disease Stool incontinence Uncontrollable diarrhea Abdominalperineal resection or other surgery leaving patient without a functioning rectum Patients using colostomy or ileostomy Liver function tests &gt; 3x upper limit of normal, or bilirubin test result &gt; 1.5 the upper limit of normal Calculated creatinine clearance &lt;60 mL/minute Planned hyperfractionated or split course radiation Planned brachytherapy prior to completion of all external beam radiation therapy Prior pelvic RT An ongoing infection ECOG score &gt;/= 3 Leukopenia &lt;2,000 WBC/mm3 or Hg &lt;10.5 g/dL Participation in an investigational drug trial within the previous 30 days Patients with a medical condition that would interfere with study compliance Known hypersensitivity to 5FU or capecitabine Anticipated inability to tolerate oral administration of SGX201 Pregnant or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>